Pictet Asset Management Ltd. cut its holdings in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 9.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 141,029 shares of the biotechnology company’s stock after selling 14,900 shares during the period. Pictet Asset Management Ltd. owned about 0.19% of Momenta Pharmaceuticals worth $2,609,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of MNTA. UBS Asset Management Americas Inc. increased its stake in Momenta Pharmaceuticals by 120.3% during the first quarter. UBS Asset Management Americas Inc. now owns 22,250 shares of the biotechnology company’s stock worth $297,000 after purchasing an additional 12,151 shares during the period. Teachers Advisors LLC increased its stake in Momenta Pharmaceuticals by 31.6% during the first quarter. Teachers Advisors LLC now owns 515,384 shares of the biotechnology company’s stock worth $6,880,000 after purchasing an additional 123,712 shares during the period. Legal & General Group Plc increased its stake in Momenta Pharmaceuticals by 2.4% during the first quarter. Legal & General Group Plc now owns 112,463 shares of the biotechnology company’s stock worth $1,501,000 after purchasing an additional 2,603 shares during the period. Thrivent Financial For Lutherans increased its stake in Momenta Pharmaceuticals by 6.7% during the first quarter. Thrivent Financial For Lutherans now owns 36,620 shares of the biotechnology company’s stock worth $489,000 after purchasing an additional 2,300 shares during the period. Finally, Vanguard Group Inc. increased its stake in Momenta Pharmaceuticals by 3.4% during the first quarter. Vanguard Group Inc. now owns 5,953,677 shares of the biotechnology company’s stock worth $79,481,000 after purchasing an additional 195,996 shares during the period. Institutional investors own 91.19% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Pictet Asset Management Ltd. Sells 14,900 Shares of Momenta Pharmaceuticals, Inc. (MNTA)” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.dailypolitical.com/2017/11/14/pictet-asset-management-ltd-sells-14900-shares-of-momenta-pharmaceuticals-inc-mnta.html.

A number of analysts have issued reports on MNTA shares. Goldman Sachs Group, Inc. (The) started coverage on shares of Momenta Pharmaceuticals in a research note on Thursday, September 28th. They set a “neutral” rating and a $18.00 price target on the stock. Zacks Investment Research lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Robert W. Baird lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating and cut their price target for the stock from $22.00 to $15.00 in a research note on Friday, October 6th. Cowen and Company set a $15.00 price target on shares of Momenta Pharmaceuticals and gave the stock a “hold” rating in a research note on Wednesday, November 1st. Finally, ValuEngine lowered shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, October 6th. Three research analysts have rated the stock with a sell rating and nine have assigned a hold rating to the company. The company presently has an average rating of “Hold” and an average price target of $15.00.

Shares of Momenta Pharmaceuticals, Inc. (NASDAQ MNTA) opened at $12.90 on Tuesday. Momenta Pharmaceuticals, Inc. has a one year low of $11.85 and a one year high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.03. The firm had revenue of $24.09 million during the quarter, compared to the consensus estimate of $29.58 million. Momenta Pharmaceuticals had a negative return on equity of 16.20% and a negative net margin of 55.61%. The firm’s quarterly revenue was down 17.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.26) earnings per share. equities analysts predict that Momenta Pharmaceuticals, Inc. will post -1.16 earnings per share for the current year.

In related news, President Craig A. Wheeler sold 35,667 shares of the company’s stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $19.03, for a total value of $678,743.01. Following the completion of the transaction, the president now directly owns 286,121 shares of the company’s stock, valued at $5,444,882.63. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Craig A. Wheeler sold 4,116 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $15.07, for a total value of $62,028.12. Following the completion of the transaction, the president now directly owns 269,231 shares of the company’s stock, valued at $4,057,311.17. The disclosure for this sale can be found here. Insiders sold 61,773 shares of company stock valued at $1,111,680 over the last ninety days. 4.40% of the stock is currently owned by corporate insiders.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.